Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder
Toronto, Canada – January 20, 2025 – Awakn Life Sciences Corp. (CSE: AWKN, OTCPIN: AWKNF, FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use…